Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Open-Label Study of Cetuximab and Bevacizumab Alone or in Combination With Fixed-Dose Rate Gemcitabine as First-Line Therapy of Patients With Metastatic Adenocarcinoma of the Pancreas

NCT00326911 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00326911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00326911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Open-Label Study of Cetuximab and Bevacizumab Alone or in Combination With Fixed-Dose Rate Gemcitabine as First-Line Therapy of Patients With Metastatic Adenocarcinoma of the Pancreas
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2006
Completion date
December 31, 2008
Enrollment
61 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer